Not a mystery molecule
Unlike most research peptides, the parent of TB-500 isn't exotic at all. Thymosin β4 is a small protein your body produces naturally — released by platelets and immune cells right at the site of an injury.
Researchers found it works by binding actin, a building block of the cell's skeleton. That lets cells move: it mobilizes stem and progenitor cells, helps them migrate into damaged tissue, encourages new blood vessels, and tamps down inflammation and scar formation.
Where the evidence is strongest
Decades of work — much of it from Allan Goldstein's group — show thymosin β4 accelerates skin healing in animal models, including the hard cases: diabetic wounds, aged tissue, and burns.
It went further than most peptides into the clinic: Phase 2 trials for pressure and stasis ulcers and a rare blistering skin condition, and Phase 3 trials for dry eye and corneal injury. Across that work it was reported as safe and well tolerated.
The TB-500 asterisk
Here's the nuance that gets lost: the robust clinical research is on thymosin β4 itself. "TB-500" is a related, lab-made fragment of that molecule.
The fragment is easier to synthesize and is what's typically sold, but you can't assume the parent peptide's evidence transfers one-to-one. The science underneath is real; the specific thing in the vial may not be the thing that was trialed.
One of the better-researched regenerative peptides — but the strong clinical data is for thymosin β4 in skin and eye repair, not the gym-recovery use of the TB-500 fragment. Solid foundation, important fine print.